Rimexolone

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	VEXOL	—	1994-12-30	fda.gov ↗

today

US approved 1994

NCT00471419 · Ph 3

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00471419	Jul 2006 → Aug 2007	dry eye syndrome	Alcon Research	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT02816905 Comparator	Oct 2015 → Jun 2016	ocular hypertension	Cairo University	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Rimexolone	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00471419 ↗ 1 NCT02816905 ↗
Known as	FID 109980	“The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.” NCT00471419 ↗
Known as	ORG 6216	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200617 ↗
Known as	Rimexolon	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200617 ↗
Known as	Rimexolona	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200617 ↗
Known as	Vexol	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200617 ↗
Action	Activate	“Glucocorticoid receptor agonist” CHEMBL1200617 ↗
Modality	Other / unclassified	“Topical steroid” NCT02816905 ↗
Route	Topical	“40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks.” NCT02816905 ↗
Target	NR3C1	“Glucocorticoid receptor agonist” CHEMBL1200617 ↗